Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422876 | 0.81 | PTGS2 (0.66) | MKNK1MKNK2PTGS2PTGS1MAP4K4 | |
| SCHEMBL2950525 | 0.78 | MKNK1 (0.60) | MKNK1MKNK2CHEK2 | |
| SCHEMBL1091006 | 0.76 | MAP4K4 (0.76) | MKNK1MKNK2MAP4K4CHEK2 | |
| SCHEMBL29933950 | 0.70 | MKNK1 (0.51) | MKNK1MKNK2 | |
| SCHEMBL14422878 | 0.69 | PTGS2 (0.65) | PTGS2PTGS1MAP4K4ABCC4ABCB11 | |
| SCHEMBL28264223 | 0.69 | MKNK1 (0.61) | MKNK1MKNK2PTGS1CHEK2 | |
| SCHEMBL3898826 | 0.69 | MKNK1 (0.57) | MKNK1MKNK2CHEK2 | |
| SCHEMBL2688812 | 0.68 | CHEK2 (0.58) | MKNK1MKNK2MAP4K4CHEK2 | |
| SCHEMBL5991770 | 0.68 | HPGDS (0.49) | MKNK1MKNK2 | |
| SCHEMBL17485151 | 0.68 | MAPK11 (0.48) | CHEK2MAPK14GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | KCNMA1, KCNMB1, KCNA1 | MKNK1 764/4885MKNK2 832/4885PTGS2 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.